Unanswered questions in frontline bladder cancer
Phillip Palmbos, MD, PhD, assistant professor, University of Michigan Health, Assistant Professor, University of Michigan Health, describes 4 key unmet questions in the first-line and neoadjuvant bladder cancer settings.
The first question is whether or not there is a role for combination chemoimmunotherapy in first-line bladder cancer in light of the phase 3 IMvigor130 (NCT02807636) and KEYNOTE-361 (NCT02853305) trials not demonstrating a statistically significant improvement in overall survival with frontline chemoimmunotherapy combinations. The second question is whether or not there is a role for newer antibody-drug conjugates, such as enfortumab vedotin and sacituzumab govitecan, with or without chemotherapy in earlier stages of disease. The third question is, “What’s the role of immunotherapy and other new agents in the neoadjuvant space?” and the fourth question is, “What is the optimal adjuvant therapy for high-risk muscle-invasive bladder cancer patients who did not receive prior chemotherapy in the neoadjuvant space?”
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.
